Skip to Content

Neupopeg

Active Substance: pegfilgrastim
Common Name: pegfilgrastim
ATC Code: L03AA13
Marketing Authorisation Holder: Dompé Biotec S.p.A.
Active Substance: pegfilgrastim
Status: Withdrawn
Authorisation Date: 2002-08-22
Therapeutic Area: Neutropenia Cancer
Pharmacotherapeutic Group: Immunostimulants

Therapeutic Indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

The marketing authorisation for Neupopeg has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide